ORIC Pharmaceuticals Extends Cash Runway with $244M Raise, Reports Best-in-Class Phase 1b Data
ORIC raised $244M in 2025 to extend cash runway to 2H 2028, with multiple Phase 3 trial initiations and data readouts in 2026 for rinzimetostat and enozertinib. Phase 1b data showed rinzimetostat achieved 55% PSA50 responses and 59% ctDNA clearance, while enozertinib delivered up to 100% intracranial ORR.
1. Operational and Financial Highlights for 2025
ORIC Pharmaceuticals completed a transformational year in 2025, securing $244 million in gross proceeds through a private placement and at-the-market equity program. As of September 30, 2025, the company held $413.0 million in cash, cash equivalents and investments, which management projects will fund operations into the second half of 2028. These resources are expected to support multiple registrational trials and key primary endpoint readouts for lead assets without near-term financing requirements.
2. Rinzimetostat (ORIC-944) Phase 1b Data in mCRPC
In a completed dose exploration study, ORIC selected provisional recommended Phase 2 doses for rinzimetostat in combination with darolutamide and apalutamide. Among 20 metastatic castration-resistant prostate cancer patients, 55% achieved a confirmed PSA50 response and 20% achieved PSA90. Circulating tumor DNA analyses in 17 evaluable patients showed >50% reduction in 76% of cases and complete clearance in 59%, exceeding clearance rates of standard-of-care comparators. The majority of treatment-related adverse events were Grade 1 or 2, supporting long-term dosing without unexpected toxicities.
3. Enozertinib Phase 1b Data in EGFR Exon 20 and PACC NSCLC
ORIC presented first-in-human data demonstrating highly competitive efficacy of enozertinib in non-small cell lung cancer patients harboring EGFR exon 20 insertion and PACC mutations. In second-line settings, systemic objective response rates exceeded historical benchmarks. In first-line cohorts, ORR reached 67% in exon 20 and 80% in PACC, with intracranial ORR of 100% in both groups among patients with measurable brain metastases. Safety was favorable, with low discontinuation rates and no significant off-target toxicities reported.
4. Anticipated Clinical Milestones and Leadership Strengthening
ORIC plans multiple data readouts in 2026, including dose optimization results for rinzimetostat in the first quarter and initiation of a global Phase 3 registrational trial in the first half. For enozertinib, the company expects monotherapy and combination data in first-line EGFR exon 20 and PACC settings in the second half. In 2025, ORIC also bolstered its management team with the appointment of Kevin Brodbeck, PhD, as Chief Technical Officer, underlining its commitment to advancing late-stage development and manufacturing readiness.